For the first time in Oncology! Molecular Profiling of the tumor using liquid biopsy
The new prime DX® Liquid test also consists of a panel of 1021 genes, which analyses immunotherapy biomarkers TMB, MSI, HLA, allowing the treating physician to plan an effective treatment for the patient, including immunotherapy, chemotherapy, PARP inhibitors and compatibility of participation in clinical trials.
In addition,prime DX® Liquid, analyses genes involved in genetic predisposition to cancer, thus providing information to the physician about the likelihood of an inherited cancer syndrome.
Recommended for the following cases:Molecular profiling of the tumor tissue with details on specific gene mutations and interactive access to information related to the specific gene
Suggested approved therapies that can be of great benefit to the specific patient with interactive access to clinical studies.
Suggested approved therapies that can be of great benefit to the specific patient with interactive access to clinical studies.
Suggested investigational therapies with interactive access to clinical studies.
Treatments with associated resistance that will not be of benefit to the specific patient.
Medication suggestions with documented indications.
The new prime DX® test is based on advanced molecular technology using hybridization capture NGS with UMIs. The test uses the Oncology Multi-Gene Variant Assay (GenePlus), which is a qualitative in vitro diagnostic test (CE-IVD) that detects variants in 1021 tumour-related genes and gene rearrangements/mergers in 38 genes.
It analyses biomarkers for response to immunotherapy, including HLA detection and biomarkers for response to chemotherapy.
The MGI-DNBSEQ-G400 is a CE-IVD platform that enables simultaneous processing of multiple samples with high sensitivity and specificity, producing faster, reliable results at a lower cost
Which patients are eligible for the test?
All patients with a solid tumour when there is insufficient tissue or recent biopsy are suitable.
How long does it take to get my results?
15 business days
What kind of sample and how much is required for the test?
For the prime DX Liquid analysis we need blood in special vials that you will receive from Genekor. (Cell-Free DNA BCT®(10ml) και Cell-Free RNA BCT®(10ml)).
Why is it necessary to analyse so many genes?
As more and more targeted therapies target gene changes that are detected in a small number of patients, a multi-gene panel results in the production of a large volume of multi-level valuable information, greatly increasing the likelihood of finding a personalized treatment plan for the patient.
It has also been shown that the more genes analysed, the more reliable the results for TMB.
Why should I sign the consent form?
For the use of the patient’s genetic material for testing, ELOT EN ISO9001:2008 and ELOT EN ISO15189:2012 require the written consent of each patient.
Are there any special transportation conditions?
Regarding the specific instructions for collecting the prime DX Liquid blood sample click here for more information.
Is the test covered by any public/private insurance?
For information about the cost coverage of the test you should contact your insurance company.
How do I make the payment for the test?
Payment can be made by bank transfer or debit/credit card.
How can I send my sample?
To schedule pickup and return of your sample, please contact us.
How will I receive my results?
Your results are shared with your GP via email.
Our Customer Service Team is committed to answer your questions with regards to the services offered by Genekor. If you would like to order any of the tests that Genekor performs please contact us directly.
*To complete the test, you are required to complete and send the Consent form that you will find on the link below.
*For more information on scientific content please contact: scientific.support@genekor.com
*Download the promotional brochure here.
*Order in the United Arab Emirates here.